April 2024 in “Clinical and experimental dermatology” This retrospective study evaluated the use of tofacitinib as an induction therapy for severe alopecia areata and found it promising and comparable to the standard oral mini-pulse treatment, though pulse steroids may be considered if tofacitinib response is inadequate.
2 citations
,
November 2023 in “Acta dermato-venereologica” This study involving 126 patients found that tofacitinib has high effectiveness and an acceptable safety profile for treating alopecia areata, with a 33.8% complete response rate at 24 weeks and sex as an independent risk factor for outcomes.
October 2023 in “The Cochrane library” This review identified that baricitinib increases both short- and long-term hair regrowth in patients with alopecia areata compared to placebo, but found inconclusive results for serious adverse effects, while evidence for other treatments remains very uncertain.
September 2023 in “British Journal of Dermatology” In this study, researchers identified subgroups of patients with severe alopecia areata treated with baricitinib who experienced early, gradual, or late hair regrowth, finding that response was influenced by baseline disease severity and duration of hair loss.
75 citations
,
March 2023 in “JAMA Dermatology” This study reported that the prevalence of alopecia areata in the US slightly increased from 0.199% to 0.222% between 2016 and 2019, with higher rates observed in women and adults.
40 citations
,
August 2022 in “Frontiers in immunology” This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.
8 citations
,
June 2022 in “Frontiers in Medicine” This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.
11 citations
,
January 2018 in “Acta dermato-venereologica” In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.
290 citations
,
December 2017 in “Journal of The American Academy of Dermatology” This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.
